Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22236089 | 1.00 | KCNH2 (0.35) | KCNH2POLBTDP1HCRTR1HCRTR2 | |
| SCHEMBL22235381 | 1.00 | KCNH2 (0.35) | KCNH2POLBTDP1HCRTR1HCRTR2 | |
| SCHEMBL22235322 | 0.90 | CYP1A1 (0.36) | — | |
| SCHEMBL22235544 | 0.83 | KCNH2 (0.36) | KCNH2POLBTDP1HCRTR1HCRTR2 | |
| SCHEMBL22235315 | 0.83 | APLNR (0.32) | — | |
| SCHEMBL22236118 | 0.83 | APLNR (0.32) | — | |
| SCHEMBL22235424 | 0.83 | KCNH2 (0.36) | KCNH2POLBTDP1HCRTR1HCRTR2 | |
| SCHEMBL22235412 | 0.83 | KCNH2 (0.36) | KCNH2POLBTDP1HCRTR1HCRTR2 | |
| SCHEMBL22235362 | 0.83 | APLNR (0.32) | — | |
| SCHEMBL29728945 | 0.83 | APLNR (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3911653-A1 | SUBSTITUTED POLYCYCLIC CARBOXYLIC ACIDS, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2021-11-24 | — | — | EP | disclosed |
| WO-2020150366-A1 | SUBSTITUTED POLYCYCLIC CARBOXYLIC ACIDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-07-23 | — | — | WO | disclosed |